Company / Return on Equity (ROE)
AbbVie Return on Equity (ROE) History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
128.7%
FY2024
5-year range
46.9% / 128.7%
FY2020-FY2024
Trend
+174.1%
vs FY2023
Sector context
#2 of 190
Health Care
What the data says
Among 190 Health Care companies, AbbVie is in the top 1% for return on equity (roe). Return on Equity (ROE) returned to growth in FY2024 after 2 years of decline, reaching 128.7%.
Based on SEC 10-K filings.
128.7% in FY2024 with a 3-year CAGR of +53.8%. Ranks 2nd among 190 companies in Health Care.
Improved from 68.6% to 128.7% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +53.8pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Top 1% in Health CareTop 1% of 190This company 128.7% Sector average -50.3%
▼
+356.0% above sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) increased 174.1% year-over-year.
- Currently 178.9pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | 128.7% | +174.1% |
| FY2023 | 46.9% | -31.6% |
| FY2022 | 68.6% | -8.4% |
| FY2021 | 74.9% | +112.2% |
| FY2020 | 35.3% | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | 104.2% | -18.9% |
| FY2016 | 128.4% | -1.5% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026